ARBB Arbuthnot Banking Group

Q&A on Arbuthnot Banking Group (ARBB): 1H’24 results - multiple options to get the most from the franchise

Hardman & Co Research
Q&A on Arbuthnot Banking Group (ARBB): 1H’24 results - multiple options to get the most from the franchise

06-Aug-2024 / 12:45 GMT/BST
The issuer is solely responsible for the content of this announcement.

Hardman & Co analyst interview | Banks

Q&A on Arbuthnot Banking Group (ARBB) | 1H’24 results: multiple options to get the most from the franchise

Arbuthnot Banking Group plc (ARBB) is the topic of conversation when Hardman & Co analyst Mark Thomas joins DirectorsTalk Interviews.

In this latest interview, Mark Thomas offers an in-depth analysis of Arbuthnot Banking Group's performance and strategic direction as highlighted in his latest report entitled . Mark explores the key findings from the company’s 1H’24 results, the factors behind its profit decline, strategies for navigating a falling rate environment, growth in specialist SME financing, credit quality and potential risks. Mark provides a comprehensive overview of how ARBB is positioning itself to maximise franchise value amidst changing economic conditions.

Listen to the interview .

 

If you are interested in meeting the company, you can register your interest

To contact us:

Hardman & Co
9 Bonhill Street

London

EC2A 4DJ

Follow us on X @HardmanandCo

Analyst:

Mark Thomas



 

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1962127  06-Aug-2024 

fncls.ssp?fn=show_t_gif&application_id=1962127&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
06/08/2024

Underlying

ARBBArbuthnot Banking Group

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arbuthnot Banking Group

Mark Thomas ... (+2)
  • Mark Thomas
  • Nigel Hawkins
ARBB Arbuthnot Banki...
RECI Real Estate Cre... ... (+8)

Hardman & Co Monthly: March 2025

In this month's feature article, we review the energy situation in the UK. On the domestic front, Ofgem has recently announced the new price cap figure of £1,849 for a typical household’s annual use of gas and electricity; this figure represents an increase of 6.4% over the January-March 2025 price cap. UK energy policy has changed of late, following the election of a Labour government last summer. The quest for Net Zero by 2030 – a hardly realistic target – is now a priority. Rightly or wrong...

ARBB ARBUTHNOT BANKING GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
ACSO ACCESSO TECHNOLOGY GROUP
VTAS VOLTA FINANCE (GBP)
HAT H&T GROUP
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
A0MXLB NB PRIVATE EQUITY PARTNERS
02/28/25 February 28, 2025 1 EN
Keith Hiscock ... (+2)
  • Keith Hiscock
  • Mark Thomas
ARBB Arbuthnot Banki...
RECI Real Estate Cre... ... (+8)

Hardman & Co Monthly: February 2025

Feature article: The October 2024 Budget - We got it wrong By Keith Hiscock, CEO at Hardman & Co In this month's feature article, we review the effects of the 2024 Budget and consider what might happen in the coming months. Our Hardman Monthly of October 2024 looked forward to the first Labour Budget for 14 years. The main theme was that, because the new Chancellor, Rachel Reeves, had ruled out increases in taxes on ‘working people’, investors would bear the brunt of any tax increases to fill ...

ARBB ARBUTHNOT BANKING GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
ACSO ACCESSO TECHNOLOGY GROUP
VTAS VOLTA FINANCE (GBP)
HAT H&T GROUP
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
A0MXLB NB PRIVATE EQUITY PARTNERS
02/03/25 February 3, 2025 1 EN
Brian Moretta ... (+3)
  • Brian Moretta
  • Mark Thomas
  • Martin Hall
SN. SMITH & NEPHEW ...
AGL ANGLE PLC ... (+62)

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...

SN. SMITH & NEPHEW PLC
AGL ANGLE PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
01/10/25 January 10, 2025 1 EN
Free Trial
ARBB Arbuthnot Banki...

Arbuthnot Banking Group: 1 director

A director at Arbuthnot Banking Group bought 116,000 shares at 900p and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

ARBB ARBUTHNOT BANKING GROUP
11/26/24 November 26, 2024 1 EN
RARMF Rare Earth Mine...
OMI. Orosur Mining I... ... (+10)

Hybridan Small Cap Feast - 17 October 2024

* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s baking in the oven? ITF announced:*** Potential** Initial Public Offerings: 30th September 2024: Applied Nutrition, the sports nutrition, health ...

RARMF RARE EARTH MINERALS PLC
OMI. OROSUR MINING INC
ARBB ARBUTHNOT BANKING GROUP
CAM CAMELLIA PLC
ALNOV NOVACYT SAS
PYC PHYSIOMICS PLC
PREM PREMIER AFRICAN MINERALS
OHG ONE HERITAGE GROUP
HE1 HELIUM ONE GLOBAL
AOM ACTIVEOPS PLC
10/17/24 October 17, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch